Product Description: Ranibizumab (RG-6321) (anti-VEGF) is a humanized anti-VEGF monoclonal antibody fragment and can recognize all VEGF-A isoforms (VEGF110, VEGF121, and VEGF165)[1]. Ranibizumab (anti-VEGF) slows vision loss in vivo and is used for wet age-related macular degeneration (AMD) research[1].
Applications: Neuroscience-Neuromodulation
Formula: N/A
References: [1]Mustafa Şahiner, et al. The Effects of Anti-Vascular Endothelial Growth Factor Drugs on Retinal Pigment Epithelial Cell Culture. Turk J Ophthalmol. 2018 Aug;48(4):190-195./[2]K J Kim, et al. The vascular endothelial growth factor proteins: identification of biologically relevant regions by neutralizing monoclonal antibodies. Growth Factors. 1992;7(1):53-64./[3]Richard Filek, et al. Safety of anti-VEGF treatments in a diabetic rat model and retinal cell culture. Clin Ophthalmol. 2019 Jul 1;13:1097-1114.
CAS Number: 347396-82-1
Molecular Weight: N/A
Compound Purity: 98.51
Research Area: Cardiovascular Disease
Solubility: H2O
Target: VEGFR
English
Deutsch
